Psyched Wellness is led by a strong team of experts, and currently engaged in Pre-Clinical Trials of AME-1, its proprietary extract of Muscimol.
Canada - CSE
Frankfurt
OTCQB
Common Shares | 135,514,695 |
Warrants | 23,886,365 |
Options | 13,275,000 |
RSU's | 4,650,000 |
Fully Diluted | 177,701,060 |
Issued and Outstanding | 135,789,695 |
The company has identified a path to market and is on track to commence commercialization of AME-1 derived products for the first half of 2022.
Psyched Wellness is the first company to bring the Amanita Muscaria to the market for human consumption in a standardized and safe product
The product is backed by science, patented, and trademarked to Psyched Wellness
We plan to have sustainable revenue from 2022 onwards
Psyched Wellness Ltd. Is a Canadian-based Life Sciences company focused on the research and development of a legal psychedelic mushroom called Amanita Muscaria. The company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.